GeneSight Cost, Insurance Coverage & Alternatives (2026 Independent Guide)
11 min read · Last reviewed: March 2026 · DecodeMyBio Editorial Team
This article is for educational purposes only. It is not medical advice, diagnosis, or treatment. Discuss pharmacogenomic testing options and costs with your healthcare provider and insurance plan.
GeneSight is a pharmacogenomic test that analyzes how your genes may affect your response to certain psychiatric medications. It is one of several options available for people considering DNA-based medication guidance — but it is also the one people search the most questions about, particularly around pricing, insurance coverage, and whether alternatives exist.
This guide consolidates what is publicly known about GeneSight costs, insurance policies, clinical evidence, and alternative approaches into a single independent reference. DecodeMyBio is not affiliated with Myriad Genetics (the company behind GeneSight) or any other testing provider referenced below.
Already have DNA data from 23andMe or AncestryDNA?
Your existing raw data file contains pharmacogenomic variants that can be analyzed against published CPIC guidelines — no new test, prescription, or insurance pre-authorization required.
Upload your data · View a sample report · Compare testing options
How Much Does GeneSight Cost in 2026?
GeneSight's published self-pay price is $330 for patients without insurance or whose insurance does not cover the test. Myriad Genetics states that 98% of patients pay $330 or less out-of-pocket. However, actual costs depend on insurance status, plan type, and whether prior authorization is obtained.
The table below summarizes typical cost scenarios. For a full breakdown including payment plans and the 2025 UnitedHealthcare policy change, see our detailed GeneSight cost analysis.
| Payer | Typical Patient Cost | Notes |
|---|---|---|
| Medicare Part B | $0 | Covered when ordered by enrolled provider for FDA-indicated conditions |
| Medicaid | Varies by state | Some state plans cover multi-gene PGx; others require prior auth or deny coverage |
| BCBS | $0–$330 | Coverage varies by state plan; some BCBS plans classify as experimental |
| Tricare | $0–$330 | Generally covers when clinical criteria are met; prior auth may be required |
| UnitedHealthcare | Likely $330 | UHC updated policy effective Jan 1, 2025 — multi-gene PGx panels are not covered under the current commercial policy |
| Self-pay (no insurance) | $330 | Payment plans available through GeneSight |
| Genomind PGx | $399 (self-pay) | Tests 24 genes; separate insurance reimbursement process |
Myriad offers a financial assistance program for patients who qualify based on income. Patients can also request a cost estimate before testing by calling GeneSight's billing line.
Does Insurance Cover GeneSight?
Insurance coverage for GeneSight and similar multi-gene pharmacogenomic panels varies significantly by payer, state, and clinical indication. Below is what is currently known for major insurance categories.
Medicare
Medicare Part B has a Local Coverage Determination (LCD) that covers pharmacogenomic testing for patients with certain conditions when ordered by an eligible provider. GeneSight is typically covered at $0 patient cost under this determination. This is the most consistent coverage pathway.
Medicaid
Medicaid coverage depends on the state. Some state Medicaid programs cover pharmacogenomic testing for psychiatric indications, while others classify it as investigational or require prior authorization. Patients on Medicaid should contact their state plan directly before proceeding. If denied, Myriad's financial assistance program may apply.
Blue Cross Blue Shield (BCBS)
BCBS is a federation of independent companies, so coverage policies differ by state and plan. Some BCBS plans cover GeneSight for treatment-resistant depression or when a patient has tried multiple medications. Other BCBS plans classify multi-gene PGx panels as experimental and do not cover them. Check with your specific BCBS plan.
Tricare
Tricare generally covers pharmacogenomic testing when clinical criteria are met and the test is ordered by a Tricare-authorized provider. Prior authorization may be required. Coverage has been reported for treatment-resistant depression and other qualifying conditions.
UnitedHealthcare (2025 update)
Effective January 1, 2025, UnitedHealthcare updated its commercial policy for multi-gene pharmacogenomic panels. Under the current policy, multi-gene PGx panels like GeneSight and Genomind are generally not covered for commercial plan members. This affects a significant number of patients. For details on the policy change and its implications, see our GeneSight cost page.
What If Insurance Does Not Cover It?
If your insurance plan does not cover GeneSight or another clinical PGx panel, several options exist:
- Self-pay at $330: GeneSight caps out-of-pocket at $330 for most patients regardless of insurance status.
- Payment plans: Myriad offers interest-free payment plans for the self-pay amount.
- Financial assistance: Income-based assistance is available for qualifying patients.
- Appeal the denial: If your claim is denied, you can file an appeal. Ask your prescriber for supporting clinical documentation.
- Raw data analysis as an alternative: If you already have DNA data from 23andMe, AncestryDNA, or another consumer test, you can upload your raw data for pharmacogenomic analysis at a fraction of the cost. This approach uses published CPIC guidelines but is informational, not a clinical diagnostic.
GeneSight Reviews — What Does the Evidence Say?
GeneSight is the most widely used pharmacogenomic test in psychiatry, with over 2 million tests administered. The primary clinical evidence comes from the GUIDED trial (2019), a randomized controlled study of 1,167 patients with treatment-resistant depression.
The GUIDED trial found that patients whose prescribers had access to GeneSight results showed a higher response rate (26% vs 20%) and remission rate (15.3% vs 10.1%) at 8 weeks. The study's primary endpoint (HAM-D17 score change at 8 weeks) was not statistically significant (p=0.107), though several secondary endpoints reached significance.
Patient experiences are mixed. Common positive themes include faster identification of effective medications and reduced trial-and-error. Criticisms include limited gene coverage (15 genes), the proprietary algorithm that does not fully align with CPIC guidelines, and cost concerns when insurance does not cover the test.
For a full evidence analysis including patient experience themes, FDA context, and study limitations, see our GeneSight reviews and evidence analysis.
Alternatives to GeneSight
GeneSight is not the only pharmacogenomic testing option. The table below compares the main approaches available in 2026. For a detailed comparison including clinical framework differences, see our full alternatives comparison.
| Option | Cost | Provider Required | Genes Tested | Type |
|---|---|---|---|---|
| GeneSight | $330 self-pay | Yes | 15 | Clinical diagnostic |
| Genomind Professional PGx | $399 self-pay | Yes | 24 | Clinical diagnostic |
| Hospital PGx programs | Varies | Yes | Varies | Clinical diagnostic |
| Raw data analysis (e.g., DecodeMyBio) | $49–$59 | No | SNP-dependent (consumer chip coverage) | Informational |
Clinical panels are ordered by a prescriber, processed in CLIA-certified labs, and detect structural variants (gene deletions and duplications). Raw data analysis uses published CPIC guidelines on existing consumer DNA data but cannot detect structural variants. The two approaches are not equivalent — see our DNA test for medication guide for a detailed explanation of the differences.
Who Might Consider GeneSight?
Pharmacogenomic testing may be relevant in several clinical scenarios. The strongest evidence base exists for patients who have:
- Treatment-resistant depression: The GUIDED trial specifically enrolled patients who had failed at least one prior medication trial.
- Multiple medication failures: Patients who have tried two or more medications without adequate response may benefit from understanding their metabolizer status for key drug-metabolizing enzymes like CYP2D6 and CYP2C19.
- Prior adverse drug reactions: Unexpected side effects at standard doses can sometimes be explained by poor metabolizer status or drug-gene interactions.
- Polypharmacy concerns: Patients taking multiple medications that share metabolic pathways may benefit from understanding potential enzyme-level interactions.
Whether to pursue clinical PGx testing, raw data analysis, or neither depends on individual clinical circumstances, insurance coverage, and the specific medications being considered. This decision should be made in consultation with a prescriber familiar with pharmacogenomics.
Explore your pharmacogenomic profile from existing DNA data
If you have 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA raw data, DecodeMyBio can map your variants against CPIC-published guidelines for CYP2D6, CYP2C19, CYP2C9, and other pharmacogenes.
Frequently Asked Questions
How much does GeneSight cost without insurance?
The maximum out-of-pocket cost for GeneSight is $330 for most patients. Myriad Genetics caps the self-pay price and offers payment plans and financial assistance for qualifying patients. See our full cost breakdown for details.
Does Blue Cross Blue Shield cover GeneSight?
BCBS coverage varies by state and plan. Some BCBS affiliates cover pharmacogenomic testing for treatment-resistant depression, while others classify multi-gene panels as experimental. Contact your specific BCBS plan for a coverage determination before testing.
Does Medicaid cover GeneSight?
Medicaid coverage for GeneSight depends on your state. Some state Medicaid programs provide coverage for pharmacogenomic testing when clinical criteria are met. Others require prior authorization or do not cover the test. Check with your state plan directly.
Is GeneSight worth it?
The answer depends on your situation. The GUIDED trial showed measurable benefits for patients with treatment-resistant depression, though the primary endpoint did not reach statistical significance. For patients who have failed multiple medications, the test may provide useful metabolizer information. For a balanced analysis, see our evidence review.
Is GeneSight FDA approved?
GeneSight is not FDA-approved as a diagnostic device. It is classified as a laboratory-developed test (LDT), which means it is developed and performed within a single CLIA-certified laboratory. The FDA has not cleared or approved GeneSight's specific algorithm or clinical claims, though the underlying genotyping technology is well established.
What are alternatives to GeneSight?
Alternatives include Genomind Professional PGx Express (24 genes, $399 self-pay), hospital-based pharmacogenomics programs, and consumer raw data analysis services that use CPIC guidelines. Each approach has different trade-offs in cost, coverage, and clinical utility. See our alternatives comparison for details.
Does GeneSight test for MTHFR?
Yes, GeneSight includes the MTHFR gene in its panel. MTHFR variants (C677T and A1298C) affect folate metabolism, which has been studied in relation to depression treatment response. However, MTHFR is not a drug-metabolizing enzyme — it relates to methylation and nutrient metabolism rather than direct drug processing. For more on MTHFR, see our MTHFR C677T guide.
Can I use 23andMe instead of GeneSight?
23andMe and GeneSight serve different purposes. 23andMe is a consumer DNA test that provides raw genotype data. GeneSight is a clinical PGx panel ordered by a prescriber. However, 23andMe raw data can be analyzed against published CPIC guidelines using services like DecodeMyBio to get informational pharmacogenomic insights. This approach does not detect gene deletions or duplications and is not a clinical diagnostic. Learn how to upload your raw data.
How long does it take to get GeneSight results?
GeneSight typically delivers results within 36 hours of the lab receiving the cheek swab sample. Results are sent to the ordering provider. Genomind results take approximately 3–5 business days. Raw data analysis through DecodeMyBio generates results in minutes since the DNA data already exists.
Does GeneSight work for ADHD medications?
GeneSight includes genes relevant to some ADHD medications. CYP2D6 is involved in the metabolism of atomoxetine (Strattera), and metabolizer status can affect dosing for this drug. However, most stimulant ADHD medications (methylphenidate, amphetamine) are not primarily metabolized by the genes GeneSight tests. For more on this, see our pharmacogenomics for ADHD guide.
Medical disclaimer: This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. DecodeMyBio provides informational pharmacogenomic reports — not clinical diagnostic testing. Always consult a qualified healthcare provider before making any medication changes. DecodeMyBio is not affiliated with Myriad Genetics (GeneSight), Genomind, or any other testing provider mentioned in this article.